Menopause & midlife

HRT and Clot Risk: Why the Patch Differs From Pills

Save

Oral HRT can modestly raise blood clot risk because swallowed estrogen passes through the liver first. In the Women's Health Initiative, oral combined therapy added about 8 clots per 10,000 women a year. Transdermal estrogen, whether patch, gel, or spray, bypasses the liver and shows little or no added clot risk.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Continue in Claude

Open a chat with this article’s link already in the message, and keep asking questions there. Claude reads the article and its sources; nothing about you is included.

Continue in Claude →

The button opens the Claude desktop app and fills in the message for you to review before sending. No desktop app, or reading on a phone? Copy the prompt and paste it into any AI.

Does HRT cause blood clots?

Oral hormone therapy can raise the risk of blood clots, but the effect is smaller than the 2002 headlines implied and depends heavily on how estrogen enters the body. Swallowed estrogen passes first through the liver, where it nudges the production of clotting proteins upward 12. In the Women's Health Initiative, oral combined therapy produced roughly 8 additional blood clots in the lungs per 10,000 women each year 3.

Estrogen delivered through the skin, whether a patch, gel, or spray, largely bypasses that first pass through the liver 14. According to the North American Menopause Society, this route difference is one of the most practical levers for lowering clot risk 1. The delivery method, not just the hormone itself, shapes the danger.

Why is the patch different from the pill?

The patch and the pill differ mainly in where the estrogen goes first. An oral tablet is absorbed through the gut and travels directly to the liver before reaching the rest of the body, a route called first-pass metabolism that boosts several clotting factors 12. A transdermal patch releases estradiol steadily into the bloodstream through the skin, keeping liver exposure low 4.

Because of this, guideline bodies describe transdermal estrogen as carrying little or no added clot risk at standard doses, unlike oral forms 14. The 2026 NICE guideline states that transdermal HRT is not associated with an increased risk of venous clots 4. The choice of patch versus pill is therefore partly a clotting-safety decision.

How large is the clot risk in real numbers?

Absolute clot numbers keep the risk in proportion. Among women not using hormones, venous clots are uncommon, and oral estrogen roughly doubles that low baseline, still a small number in absolute terms 35. In the WHI, oral combined therapy added about 8 pulmonary embolisms and a similar count of leg clots per 10,000 women each year 3.

A Cochrane review of long-term hormone therapy likewise found that oral regimens increased clots and stroke, especially when started after age 60 5. Transdermal estradiol, by contrast, has not shown the same increase in large analyses 14. Recognizing clot symptoms in the leg, such as swelling, warmth, and one-sided pain, matters for anyone on oral therapy.

Who has the most reason to consider the patch?

Some women have far more reason to favor the transdermal route. A personal or family history of clots, obesity, smoking, or long stretches of immobility raises baseline clotting risk, and oral estrogen adds to it 15. For these women, guidelines lean toward a patch, gel, or spray rather than a pill 14.

Risk also shifts across life stages: clotting risk climbs with age, so a woman starting therapy under 55 generally faces a lower baseline than one beginning past 60 5. According to the North American Menopause Society, matching the route to a woman's clot risk is a core part of individualizing therapy 1. People prone to clots on long flights share some of the same vulnerability.

When HRT clot risk needs a clinician

A clinician who prescribes hormone therapy can match the route to your personal clot risk. Your history of blood clots, family patterns, weight, smoking status, and age all influence whether an oral or transdermal form makes more sense.

A gynecologist, menopause specialist, or primary care clinician can compare a patch, gel, or ring against a pill and explain the tradeoffs. Gale can help you prepare for that conversation. For many women worried about clots, learning that the delivery method changes the risk is the most reassuring part of the discussion.

Common questions

For clot risk, generally yes. Because a patch, gel, or spray delivers estrogen through the skin and largely bypasses the liver, guidelines describe transdermal forms as carrying little or no added clot risk at standard doses, while oral estrogen modestly increases it.

In absolute terms, not much. The Women's Health Initiative found oral combined therapy added roughly 8 blood clots per 10,000 women each year. That is a real but small increase, and it is larger in women who are older or already prone to clots.

Swelling, warmth, redness, or pain in one leg can signal a deep vein clot, and sudden shortness of breath or chest pain can signal a clot in the lung. These symptoms warrant urgent medical attention rather than waiting.

That is exactly the situation where clinicians often prefer a transdermal route, if hormone therapy is used at all. A personal history of clots is an important factor a clinician weighs carefully before recommending any form.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Clot warning signs on hormone therapy

  • —Swelling, warmth, or one-sided pain in a leg can signal a deep vein clot and is a reason to seek urgent medical care.
  • —Sudden shortness of breath, chest pain, or coughing up blood can signal a clot in the lung and is a reason to seek emergency care.
  • —Sudden severe headache, face or limb weakness, or slurred speech can signal a stroke and is a reason to call for emergency help.
  • —New leg redness with fever after starting oral hormone therapy is a reason to arrange prompt clinician review.

Sudden shortness of breath, chest pain, coughing up blood, or one-sided leg swelling can signal a blood clot in the lung or leg — call 911 or go to the nearest emergency room right away.

This article is general health education, not medical advice. Which form of hormone therapy fits your clot risk is a decision to make with a gynecologist, menopause specialist, or primary care clinician who knows your history.

References

  1. 1.The North American Menopause Society (Menopause Society) (2022). The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. doi:10.1097/GME.0000000000002028 ✓Consensus that transdermal estrogen carries lower clot risk than oral estrogen and that matching route to clot risk individualizes therapy.
  2. 2.MedlinePlus (National Library of Medicine) (2026). Hormone Replacement Therapy. MedlinePlus, U.S. National Library of Medicine (NIH). link ✓Patient-facing overview of hormone therapy forms and how oral estrogen is metabolized through the liver.
  3. 3.Rossouw JE, Anderson GL, Prentice RL, et al. / Writing Group for the Women's Health Initiative Investigators (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. doi:10.1001/jama.288.3.321 ✓The WHI per-10,000 absolute count of roughly 8 additional pulmonary embolisms per year with oral combined therapy.
  4. 4.National Institute for Health and Care Excellence (2026). Menopause: identification and management (NG23). National Institute for Health and Care Excellence (NICE). link ✓2026 NICE guidance that transdermal HRT is not associated with an increased risk of venous clots.
  5. 5.Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J (2017). Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD004143.pub5 ✓Cochrane systematic review finding oral hormone therapy increased venous clots and stroke, particularly with later initiation.

5 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library